![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 33, 23043-23051, August 13, 1999
From the Cyclin-dependent kinases (CDKs) play
an important role in the eukaryotic cell cycle progression. Cdc2 (CDK1)
is expressed in late G1/S phase and required for
G2 to M phase transition in higher eukaryotes. The
oncoproteins, SV40 large T antigen and adenovirus E1A, induce a 110-kDa
protein which specifically recognizes the two inverted CCAAT motifs of
the cdc2 promoter in cycling cells and plays an essential
role in transactivation of the human cdc2 promoter. Since
these CCAAT motifs also conform to the consensus binding sites for the
ubiquitous heterotrimeric transcription factor, CBF/NF-Y, the role of
CBF/NF-Y in the transactivation of the cdc2 promoter was
examined in this study. Our results indicate that CBF/NF-Y and the
110-kDa protein interact with the CCAAT box motif to form a heteromeric
complex. However, mutagenesis of the pentanucleotide CCAAT motif or in
the presence of urea greater than 2.5 M, no heteromeric
complex was formed. In contrast, the 110-kDa protein could still bind
the mutant CCAAT motif or with the wild type motif in the presence of
2.5 M urea. Furthermore, E1A.12S induced the gene
expression of all three subunits of CBF/NF-Y. Coexpression of E1A and a
dominant negative mutant NF-YA subunit significantly reduced the
E1A-mediated transactivation of the cdc2 promoter in a
dose-dependent manner. These results support the conclusion
that E1A protein mediates optimal transactivation of the human
cdc2 promoter by inducing the expression and assembly of a
heteromeric complex consisting of the 110-kDa protein and the CBF/NF-Y
which interacts with the two CCAAT motifs of the cdc2 promoter.
The progression of the eukaryotic cell cycle through quiescent to
proliferating state is tightly controlled by a periodic expression and
function of the key regulatory proteins, such as cyclins,
cyclin-dependent kinases
(CDK)1 and CDK inhibitors.
The p34Cdc2 (CDK1), the product of cdc2 gene in
S. pombe or the cdc28 gene in Saccharomyces
cerevisiae, is the first identified CDK. This CDK1 regulates both
the G1 The kinase activity of CDK1 is regulated by phosphorylation and
dephosphorylation, and is linked to the growth state of the cells (4)
(for reviews, see Refs. 12, 13, and 16). Moreover, the expression of
human cdc2 mRNA and the CDK1 levels are very low in
cells which are under growth arrest, differentiation, or development.
When the cells enter the cell cycle, the cdc2 gene expression is increased dramatically (17-22) suggesting that the CDK1
is required for proliferation. The low levels of the cdc2 gene expression in growth arrested baby rat kidney cells are also dramatically reversed by expression of the oncoproteins of DNA tumor
viruses, adenovirus E1A (E1A) and SV40 large T antigen (SV40-LT). This
activation of the cdc2 gene expression is accompanied by induction of p34Cdc2 kinase activity, pRB phosphorylation,
and DNA synthesis (22-24).
The growth promoting activities of the DNA tumor virus oncoproteins are
at least in part attributable to their ability to associate with
proteins that negatively regulate cell growth, the retinoblastoma
susceptibility gene product (pRB) and p53 (25-28) (for reviews, see
Refs. 29-31). For example, interaction of E1A and SV40-LT with pRB
disrupts the transcriptionally inactive pRB·E2F complexes resulting
in transcriptional activation of growth promoting E2F-dependent genes (26, 32-35) (reviewed in Refs.
29-31). An independent pathway by which E1A promotes cell growth is by
its association with p300/CBP which is required as a coactivator of p53
and inhibition of p53-dependent
p21Cip1/Waf1 expression resulting in the
release of cells from G1 arrest and in stimulation of
cellular DNA synthesis (36-40). The association of E1A with
p27Kip1 also has been shown to overcome the transforming
growth factor- Previous studies in our laboratory showed that E1A and SV40-LT
transactivate the human cdc2 promoter in cycling cells by
inducing a 110-kDa protein which specifically recognizes the
two-inverted CCAAT box (ATTGG in the opposite strand) motifs in the
cdc2 promoter located at positions The CCAAT motifs are present in many eukaryotic class II promoters and
are also specific binding sites for the ubiquitously expressed
heterotrimeric transcription factor, NF-Y (CBF/NF-Y). CBF/NF-Y consists
of three subunits (A, B, and C) which are all required for DNA binding
activity (44-47). Moreover, NF-Y is known to function in most cases in
conjunction with a variety of specific transcriptional activators to
achieve optimal levels of gene expression. For example, in albumin
promoter, NF-Y and CCAAT/enhancer-binding protein (C/EBP) are both
required for optimal level of liver-specific gene expression (48). The
transcriptional regulation of the 3-hydroxy-3-methylglutaryl-CoA
synthase gene involved in cholesterol biosynthetic pathway is achieved
by the sterol regulatory element-binding proteins together with
CBF/NF-Y through sterol regulatory element and the CCAAT box motif in
the promoters of target genes. A direct interaction between sterol
regulatory element-binding proteins and CBF/NF-Y was demonstrated in
that study (49).
In this study, we show that CBF/NF-Y interacts with the 110-kDa protein
induced by adenovirus E1A.12S. The formation of this heteromeric
complex is disrupted by mutagenesis of the pentanucleotide CCAAT motif
or by treatment with urea greater than 2.5 M. The 110-kDa
protein, however, could still bind the mutant DNA fragment or the wild
type DNA fragment in the presence of 2.5 M urea indicating that the protein binds to the flanking sequences of the pentanucleotide CCAAT motif. Hence it is referred as the CCAAT box-associated factor in
this study (CBAF/cdc2). Furthermore, we show that expression of E1A
increases the steady state levels of mRNAs encoding all three
subunits of CBF/NF-Y. In addition, we present evidence that the
heterotrimeric CBF/NF-Y plays an important role in transactivation of
the human cdc2 promoter by E1A based on the results that the expression of a dominant negative mutant CBF/NF-YA interferes with this
transactivation in a dose-dependent manner. Our results, taken together, suggest that E1A mediates optimal transactivation of
the human cdc2 promoter by inducing both the heterotrimeric CBF/NF-Y and the 110-kDa CBAF/cdc2 as the costimulatory factor for
NF-Y.
Cell Culture--
Human embryonic kidney cells transformed by
early region 1 of adenovirus (293 cells) were grown in Joklik's
modified Eagle's medium supplemented with 10% heat-inactivated horse
serum (Life Technologies, Inc.) in spinner suspension flasks. Fisher
rat liver epithelial cell line (RLE) cells were grown in Dulbecco's
modified Eagle's medium/F12 medium (Sigma) supplemented with 10%
fetal bovine serum and 50 µg/ml each of streptomycin and penicillin. Cells were incubated at 37 °C in humidified air containing 5% CO2.
Preparation of Nuclear Extracts--
For preparation of nuclear
extracts, RLE cells in 80% confluence were infected with adenovirus
encoding E1A.12S ((22); kindly provided by Dr. Elizabeth Moran, Temple
University) at 50 plaque forming units/cell. Cells were harvested
48 h post-infection and nuclear extracts were prepared as
described previously (42).
Electrophoretic Mobility Shift Assay--
Electrophoretic
mobility shift assays (EMSA) were carried out as described previously
(42). The double-stranded DNA was labeled at the 5'-end by T4
polynucleotide kinase and [ UV Cross-linking of DNA-Protein Complexes--
UV cross-linking
was carried out (61) as follows. A 29-bp DNA probe was made using
Klenow DNA polymerase-catalyzed fill-in reaction in the presence of
5-bromo-2'-deoxyuridine triphosphate (Sigma) and
[ Southwestern Blot Analysis--
The conditions used for
Southwestern blot analysis were as described previously (42). Briefly,
10 µg of nuclear proteins from 293 cells were loaded in each lane and
were fractionated by 8.0% SDS-PAGE. The proteins were transferred
electrophoretically to a polyvinylidene difluoride membrane (Bio-Rad).
After denaturation and renaturation steps, the proteins immobilized on
the membrane were incubated with the 5'-32P-labeled distal
or proximal cdc2/CCAAT probe (106 cpm/ml). The
membranes were washed and subjected to autoradiography.
Immunoprecipitations--
The nuclear extracts from 293 cells
were precleaned by incubation with normal rabbit serum followed by
treatment with protein-A-agarose beads (Life Technologies, Inc.). The
supernatant obtained after centrifugation was incubated with anti-NF-YA
antibody, normal rabbit serum, or an unrelated antiserum raised against
hepatitis C virus NS5A protein. The precipitated protein complex was
recovered by protein A-agarose beads. The immunoprecipitated complexes
were subsequently subjected to Southwestern blot analysis using
5'-32P-labeled distal or proximal cdc2/CCAAT
probe to detect the 110-kDa CBAF/cdc2.
Northern Blot Analysis--
Total RNAs were obtained from the
adenovirus-infected RLE cells 32 h post-infection by using Trizol
(Life Technologies, Inc.). Twenty micrograms of the RNAs were
fractionated on 1% agarose, 6% formaldehyde gel and transferred onto
nitrocellulose membrane. After heating the membrane at 80 °C for
2 h, the membrane was hybridized with a 32P-labeled
probe using the Quick-Hyb hybridization solution. Probes used for the
Northern blottings were rat NF-Ya (CBF-B) and NF-Yb (CBF-A) and NF-Yc
cDNAs (pCITE2a-CBF-A, -B, and -C were kindly provided by Dr. S. Maity, University of Texas, M.D. Anderson Cancer Center). For detection
of the cdc2 mRNA the probe used was a DNA fragment
derived from the cDNA encoding human cdc2 by digesting the
pCMV1-cdc2 plasmid (kindly provided by Dr. J. Campisi,
Lawrence Berkeley Laboratory, University of California) with
BglII and KpnI.
Chloramphenicol Acetyltransferase Assay (CAT)--
RLE cells (in
45% confluence) in 25-cm2 culture flasks were infected
with recombinant adenovirus expressing wild type 12S.E.1A. One hour
after infection, cells were transfected with cdc2
promoter-CAT reporter plasmids (cdc2-TaqI-CAT; 3 µg) (42) and various amounts of dominant negative mutant of NF-YA
(NF-YA29) (51) for 6 h in serum-free medium in the presence of
cationic lipids as described previously (42). The NF-YA29 dominant
negative expression plasmid was generously provided by Dr. Timothy F. Osborne, University of California-Davis, with kind permission from Dr.
Robert Mantovani from the University of Degli Studi Di Milano, Italy.
Cells were incubated for 40 h in Dulbecco's modified Eagle's
medium containing 10% fetal bovine serum and cell lysates were
prepared for CAT assays as described previously (42).
pRSV-Escherichia coli Human cdc2 Promoter Contains Two Inverted CCAAT Box Motifs
Which Conform to Consensus NF-Y-binding Sites and Are Recognized by the
110-kDa CBAF/cdc2 and NF-Y Next we analyzed whether the complex I also included the 110-kDa
CBAF/cdc2 protein using the UV cross-linking method. First, 32P- and 5'-bromodeoxyuridine-labeled cdc2 CCAAT
motif was used for EMSA. Subsequent to EMSA and autoradiographic
detection of the three major DNA-protein complexes (C-I to C-III), the
complex I band was cut out from the polyacrylamide gel. The gel piece was exposed to UV as described under "Experimental Procedures," and
the labeled DNA-protein complex was fractionated by SDS-PAGE and
subjected to autoradiography. The results shown in Fig. 1C indicated that two significant bands with estimated sizes of 110 and 45 kDa (lane 4) were detected, while samples with no UV
treatment served as negative control (lane 3). The 45-kDa
band is consistent with the reported size for CBF/NF-YA subunit
(47).
To further confirm that the 110-kDa CBF/cdc2 and CBF/NF-Y directly
interact, we performed the immunoprecipitation experiments with nuclear
extracts from 293 cells using anti-NF-YA antibody. The immune complex
was subjected to SDS-PAGE and Southwestern blot analysis using
32P-labeled distal CCAAT motif of the cdc2
promoter as the probe. As shown in Fig. 1D (lane
2), the results from Southwestern blot analysis showed that only
the anti-NF-YA immune complex from 293 cell extracts contained the
110-kDa CBAF/cdc2 protein (lane 2), but not the immune
complexes obtained using normal rabbit serum or an unrelated antiserum
raised against hepatitis C virus NS5A protein (lanes 1 and
3, respectively). The results taken together indicated that
the 110-kDa CBAF/cdc2 and the CBF/NF-Y formed a heteromeric complex
with the DNA fragment containing the distal CCAAT motif of the
cdc2 promoter.
Since the 293 cells are constitutively expressing proteins encoded by
the adenovirus E1 region, which encodes E1A and E1B proteins (53), we
sought to determine whether this heteromeric complex I is induced by
E1A alone. For these experiments, RLE cells were used for expression of
E1A protein by infection with a recombinant adenovirus encoding
E1A.12S. The nuclear extracts prepared from the infected RLE cells were
analyzed by EMSA. As shown in Fig. 2, the
endogenous levels of the 110-kDa CBAF/cdc2 (Fig. 2B, lane 1)
as well as the formation of complex I in EMSA (Fig. 2A, lane
2) were barely detectable in the absence of E1A expression in RLE
cells. The results shown in Fig. 2A indicate that the
formation of the heteromeric DNA-protein complex I was also induced by
transient expression of E1A.12S protein in RLE cells (lane
3). Evidence that this complex I also contained CBF/NF-Y was
obtained by supershift assays performed by incubation with antibodies
against NF-YA and NF-YB (lanes 5, 6, and 8)
whereas incubation with normal rabbit serum had no effect (lane
4). Furthermore, it is shown that E1A induces the 110-kDa
CBAF/cdc2 in RLE cells by the Southwestern blot analysis (Fig.
2B, lane 2).
Transactivation of the Human cdc2 Promoter by
Adenovirus E1A
E1A INDUCES THE EXPRESSION AND ASSEMBLY OF A HETEROMERIC COMPLEX
CONSISTING OF THE CCAAT BOX BINDING FACTOR, CBF/NF-Y, AND A 110-kDa
DNA-BINDING PROTEIN*
§,
§¶,
,
, and
**
Department of Biochemistry and Molecular
Biology, University of Kansas Medical Center, Kansas City, Kansas
66160-7421 and the
Department of Pathology and Cell Biology,
University of Occupational and Environmental Health, 1-1 Iseigaoka,
Yahatanishi, Kitakyushu 807, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
S and G2
M phase transitions
(1-9) (for reviews, see Refs. 10-13, and the references therein). In higher eukaryotes, separate CDKs are involved in these cell cycle transitions; the homologue of CDK1 is expressed in G1
S
phase and is primarily required for the G2
M phase
transition (7-9). Other CDKs are involved in G1
S
phase transitions (8, 14, 15) although the CDK1 also seems to play a
role in phosphorylation of key substrates involved in transition of the
G1
S phase (for reviews, see Refs. 12 and 16, and
references therein).
1-mediated growth arrest at G1 phase of
the cell cycle (41).
74 to
78 and
42
to
46 with respect to transcription start site (42, 43).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP following standard
procedures (50). The oligonucleotides used in this study are: 1) the
distal CCAAT element of the human cdc2 promoter
(5'-CATGGGCTCTGATTGGCTGCTTTG-3'), 2) (Mut-CCAAT) probe containing
mutated CCAAT box motif (5'-CATGGGCTCTGAggccCTGCTTTG-3'), 3) probe
containing the proximal CCAAT box-binding motif of the human
cdc2 promoter (5'-GCTACCCGATTGGTGAATCCG-3'). As a control for competition experiments in gel mobility assays, the unrelated oligonucleotide containing the E2F-like binding site of
p21Cip1 promoter (5'-CAGCTGCTCCGCGCTGGGCAGCCAG-3') was
used. For EMSA, nuclear extracts (5 µg/lane) were mixed in 20 µl of
reaction buffer (25 mM Hepes-KOH, pH 7.9, 5 mM
KCl, 0.5 mM EDTA, 0.15 mg/ml of bovine serum albumin, 0.25 mM dithiothreitol, 10% glycerol, 0.1 mg/ml poly(dI-dC)
with the labeled probe (5 × 105 cpm/lane). The
reaction mixture was incubated at 37 °C for 30 min, and stopped by
adding 2 µl of stop solution containing 50 mM EDTA,
0.05% bromphenol blue, 0.05% xylene cyanol, and 5% glycerol. The
DNA-protein complexes were fractionated by electrophoresis on 4%
nondenaturing polyacrylamide gels. The gels were dried and subjected to
autoradiography using x-ray films (NEN Life Science Products Inc.). For
supershift experiments, EMSA reaction mixtures were incubated with 1.5 to 5.0 µg of rabbit anti-NF-YA or NF-YB antibody (Rockland,
Gilbertsville, PA) for 1 h on ice prior to addition of the probes.
-32P]dCTP (NEN Life Science Products) and dNTPs. The
two primers used were partially complementary oligonucleotides with the
sequences of 5'-CATGGGCTCTGATTGGCTGCTTTG-3' and
5'-GGGGGCAAAGCA-3'. The labeled probe was added to the EMSA
reaction mixture containing 20 µg of the nuclear extract from 293 cells. DNA-protein complexes were fractionated by 4% nondenaturing
gel. The DNA-protein complexes were located by autoradiography by
exposing the gel to the x-ray film overnight at 4 °C. The band was
excised and exposed to 285 nm UV light for 15 min at 4 °C. Then the
excised gel fragment was mixed with 2 × SDS-PAGE loading buffer
and laid in the well of a 4% stacking polyacrylamide gel polymerized
over a 6% resolving gel containing 0.1% SDS. After electrophoresis,
the UV cross-linked DNA-protein complexes were detected by autoradiography.
-galactosidase expression plasmid
was co-transfected as the internal control to monitor and normalize the
transfection efficiencies.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
The two inverted CCAAT box motifs of
the human cdc2 promoter conform to the consensus
NF-Y-binding site, TGATTGG(T/C)(T/C)(A/G), derived from a random
polymerase chain reaction-based selection procedure (52). Our previous studies indicated that a 110-kDa protein (referred as CBAF/cdc2 in this
study) was induced by the oncoproteins, SV40-LT and E1A, and it was
overproduced in cells transformed by SV40 and adenovirus E1 region (COS
and human 293 cells, respectively). This protein specifically bound the
180-bp DNA fragment containing both CCAAT motifs or a 24-bp fragment
containing the distal motif (42, 43). Therefore, we sought to determine
whether DNA-protein complexes formed between the distal CCAAT motif of
the cdc2 promoter and the nuclear extracts of human 293 cells also contained the ubiquitous CBF/NF-Y. As shown in Fig.
1A (lane 2), the
nuclear extracts from human 293 cells formed three major complexes
(C-I, -II and -III) with the 32P-labeled distal CCAAT motif
used as a probe in EMSA. The specificity of these DNA-protein complexes
formed with the CCAAT motif was established by competition experiments
using unlabeled oligonucleotides containing wild type CCAAT, unrelated
E2F-binding site, or the mutated CCAAT motif (lanes 3-5,
respectively). To determine whether any of these DNA-protein complexes
also contained CBF/NF-Y, supershift assays in which rabbit polyclonal
antibodies raised against CBF/NF-YA and CBF/NF-YB subunits were
incubated with the DNA-protein complexes. The results shown in Fig.
1B (lanes 3 and 5) indicated that the antibodies against NF-YA and NF-YB supershifted the complex I, although
the commercial anti-NF-YB was much less efficient than the anti-NF-YA.
However, both antibodies had no effect on complexes II and III, which
suggested that these complexes do not include NF-Y. Moreover,
incubation with normal rabbit serum used as control (Fig. 1B,
lanes 2 and 4) had no effect. These results indicated that the DNA-protein complex I contains CBF/NF-Y. We did not test for
the presence of CBF/NF-YC in this complex because a suitable antibody
against the C subunit was not available for this study. However, the
complex I is likely to include the CBF/NF-YC as previous studies have
shown that all three subunits are required for DNA binding (47).

View larger version (49K):
[in a new window]
Fig. 1.
Interaction of the 110-kDa CBAF/cdc2 and
NF-Y. A, EMSA using nuclear extracts from human 293 cells were carried out with the labeled oligonucleotide containing the
distal wild type CCAAT box motif of the human cdc2 promoter
(dis-WT-CCAAT) as described under "Experimental Procedures." The
positions of complex I, II, and III were indicated (lane 2).
Lane 1 contained the free probe in the absence of nuclear
extracts. The competition experiments (comp.) were carried
out by adding a 100-fold excess of unlabeled cold oligonucleotide
containing the distal wild type CCAAT box motif of the human
cdc2 promoter (WT-cold), mutated CCAAT box motif
(Mut-cold), and E2F-binding site motif
(E2F-cold), and mutated CCAAT box motif
(Mut-Cold) in lanes 3-5, respectively.
B, supershift assay was carried out by incubation of nuclear
extracts with antibodies against NF-YA and NF-YB (lanes 3 and 5, respectively), 60 min before adding the labeled
distal wild type CCAAT motif as the probe. Normal rabbit serum was used
as the control (lanes 2 and 4). C, UV
cross-linking using nuclear extracts from human 293 cells were carried
out as described under "Experimental Procedures" using the labeled
distal wild type CCAAT motif as the probe. In lane 4, two
major bands, 110 and 45 kDa, were observed in UV cross-linking of
complex I (C-I) isolated from an EMSA. Lane 3 represents the C-I without UV cross-linking. Lanes 1 and
2 represent the free probe without and with UV irradiation.
D, first, immunoprecipitations using 293 cell nuclear
extracts were carried out using either normal rabbit serum (lane
1), anti-NF-YA antibody (lane 2), or anti-hepatitis C
virus NS5A antibody as an unrelated antibody control. The immune
complexes were subjected to Southwestern blot analysis using the
labeled distal wild type CCAAT as the probe as described under
"Experimental Procedures." In lane 2, the 110-kDa
CBAF/cdc2 was detected in the immune complex with anti-NF-YA
antibody.

View larger version (43K):
[in a new window]
Fig. 2.
Induction of the 110-kDa CBF/cdc2 and NF-Y
complex by E1A. A, EMSA and supershift assays were
carried out using nuclear extracts from recombinant adenovirus
expressing E1A.12S-infected RLE cells and labeled wild type distal
CCAAT element as the probe. 293 cell extract was used as a positive
control (lane 1). Lanes 2 and 3 represent EMSA using nuclear extracts from uninfected and
Ad.E1A.12S-infected RLE cells. In lane 7, cold competitor
oligonucleotide was used. Lanes 4-6 represent supershift
EMSA assays in which normal rabbit serum, anti-NF-Ya, and anti-NF-Yb,
respectively, were used as described under "Experimental
Procedures." Lane 8 represents an overexposure of
autoradiography in which the anti-NF-Yb was used for supershift EMSA.
B, the induction of the 110-kDa CBAF/cdc2 by E1A in RLE
cells was confirmed by Southwestern blot analysis using labeled distal
wild type CCAAT as the probe. Lanes 1 and 2 represent nuclear extracts from uninfected and Ad.E1A.12S-infected
cells, respectively.
Adenovirus E1A Induces Gene Expression of All Three Subunits of
CBF/NF-Y--
These results indicated that the DNA-protein complexes
containing the heterotrimeric NF-Y protein and the 110-kDa CBAF/cdc2, which interact with each other and with the CCAAT box motif of the
cdc2 promoter, were induced by the expression of adenovirus E1A protein. Next we sought to determine whether the induction of the
cdc2 gene expression by E1A is concomitant with the
induction of the heterotrimeric CBF/NF-Y gene expression. Total RNAs
isolated from RLE cells infected with recombinant adenovirus encoding
E1A.12S protein were used for Northern blot analysis. The results shown in Fig. 3A indicate that the
steady state levels of cdc2 mRNA were increased after
the expression of E1A in RLE cells as expected based on previously
reported observations in quiescent baby rat kidney cells (18, 22, 23)
and in cycling RLE cells (43). In addition, we observed that the steady
state levels of mRNAs encoding all three subunits of CBF/NF-Y were
increased in the E1A expressing cells (Fig. 3B).
|
CBF/NF-Y and the 110-kDa Protein Recognize Distinct Sequences in the Human cdc2 Promoter-- The results of our immunoprecipitation with anti-NF-YA antibody followed by Southwestern blot analyses (Fig. 1C) and EMSA (Fig. 1A) provided evidence that the 29-bp distal CCAAT motif of the cdc2 promoter recognized the 110-kDa protein and that it interacts with the heterotrimeric CBF/NF-Y. These observations raised a question regarding the sequences recognized by both proteins. Previous studies on the DNA sequences recognized by CBF/NF-Y indicated that all three subunits of CBF/NF-Y and the pentanucleotide CCAAT motif are stringently required for DNA binding (47, 54). In addition, the flanking sequences of the pentanucleotide motif have been shown to stabilize NF-Y binding (52, 54).
To address this question, we carried out EMSA using a mutant 24-bp DNA
fragment as the labeled probe which contained mutations in the CCAAT
motif but retained the flanking sequences as wild type (Mut-CCAAT). The
results shown in Fig. 4A
indicated that the heteromeric complex I was not formed with the
Mut-CCAAT motif (Fig. 4A, lane 4). However, the DNA-protein
complex formed with the Mut-CCAAT fragment had a faster electrophoretic
mobility than that of complex I (as shown by an arrow in
Fig. 4A). This fast migrating band could be competed out by
unlabeled oligonucleotides such as the Mut-CCAAT (lane 5)
and distal wild-type CCAAT motif (lane 7), but not by an
unrelated oligonucleotide such as the E2F-like binding site of the
p21Cip1 promoter (lane 6; see also Fig.
6A, lane 4). We observed that the new band which appeared in the cold competition EMSA using the wild
type CCAAT oligonucleotide (see Fig. 1A, lane 3) had similar
mobility as the faster migrating band obtained with the Mut-CCAAT (Fig.
4A, lane 4). Therefore, we performed EMSA for a longer
period and the results showed that these two bands were distinct
DNA-protein complexes. Consistent with this observation, the new band
observed in a cold competition experiment using the distal wild type
CCAAT as the labeled probe (Fig. 1A, lane 3) could not be
competed out by adding the Mut-CCAAT oligonucleotide (data not shown).
The mutation of the pentanucleotide CCAAT motif in the Mut-CCAAT
oligonucleotide would be expected to disrupt NF-Y binding based on the
previous report (52). Therefore we sought to determine whether this
faster migrating DNA-protein complex contained the 110-kDa CBAF/cdc2.
To this end, we used the 32P-labeled Mut-CCAAT fragment as
a probe for the Southwestern blot analysis using nuclear extracts from
293 cells. The results of Southwestern blot analysis shown in Fig.
4B indicate that the Mut-CCAAT motif could still recognize
the 110-kDa protein (lane 1). Moreover, binding of the
110-kDa protein to the Mut-CCAAT motif could be competed out by adding
a 50-fold excess of cold Mut-CCAAT oligonucleotide (Fig. 4B, lane
2). These results, taken together, indicated that the 110-kDa
CBAF/cdc2 interacted with the DNA sequences flanking the
pentanucleotide CCAAT motif of the cdc2 promoter.
|
|
Our results indicated that the 110-kDa protein alone was capable of specifically binding the Mut-CCAAT distal motif of the human cdc2 promoter and that this DNA-protein complex had a faster mobility than that of complex I in EMSA (indicated by an arrow in Fig. 4A). Moreover, the faster migrating DNA-protein complex could also be detected in smaller amounts in EMSA carried out with the 293 cell nuclear extracts and the wild type DNA probe (Fig. 4A, lane 2). This observation suggested that there is some free 110-kDa CBAF in 293 cell extracts not part of the heteromeric complex with the CBF/NF-Y. Therefore, we sought to determine whether the heteromeric complex I which contains NF-Y and the 110-kDa CBAF (from the results of Southwestern blot analysis and UV cross-linking) could be dissociated to the faster migrating DNA-protein complex. To this end, we analyzed the stabilities of the DNA-protein complexes by EMSA in the presence of increasing concentrations of urea. The results shown in Fig. 5A indicated that urea concentrations exceeding 2.5 M significantly disrupted the interaction between NF-Y and the 110-kDa protein such that the complex I could no longer be formed. However, the faster migrating DNA-protein complex could still be formed in the presence of urea (shown by an arrow in Fig. 5A), and it had the same mobility as the DNA-protein complex formed with the distal Mut-CCAAT probe in the absence of urea (Fig. 4A, shown by arrow). The specificity of the DNA-protein complexes formed under conditions which contained urea in EMSA reaction mixtures was established by adding 100-fold excess of cold oligonucleotides containing either the wild type or the distal Mut-CCAAT motif. In Fig. 5B, the complex I, II, III, and the fast migrating band were competed out by the cold wild type CCAAT oligonucleotide (lane 3); however, only the fast migrating band was competed by the distal Mut-CCAAT oligonucleotide (lane 4).
The Proximal CCAAT Motif of the Human cdc2 Promoter Is Also
Recognized by the Heteromeric Complex between NF-Y and the 110-kDa
Protein--
Since the proximal inverted CCAAT motif of the human
cdc2 promoter has the consensus sequences for NF-Y binding,
we analyzed the interaction of the heteromeric complex from 293 cell
nuclear extracts to a 21-bp oligonucleotide probe containing the
proximal CCAAT motif by EMSA. Interestingly, the results shown in Fig. 6A indicated that only complex
I was formed with the proximal motif (lane 2) and this
pattern was similar to the results obtained with the CCAAT element of
the cyclin A promoter (see Ref. 62). This DNA-protein
complex was competed out with cold wild type oligonucleotide but not
the unrelated oligonucleotide containing the E2F-like binding site of
the p21Cip1 promoter (lane 4). The presence of
NF-Y in complex I was confirmed by supershift EMSA using either normal
rabbit serum as negative control (lane 5) or the anti-NF-Ya
and NF-Yb antibodies (lanes 6 and 7,
respectively). Upon longer exposure during autoradiography, we could
see the supershifted band obtained with the anti-NF-Yb antibody (data
not shown) similar to the results shown in Fig. 2A
(lane 8). The presence of the 110-kDa protein in this
complex formed with the proximal motif was confirmed by Southwestern
blot analysis (Fig. 6B). This interaction is specific as
shown by the result that a 50-fold excess of the unlabeled proximal
CCAAT motif reduced this interaction significantly (Fig. 6B, lane
2).
|
NF-Y Plays an Important Role in Transactivation of the Human cdc2
Promoter by Adenovirus E1A Protein--
Since our results showed that
the oncoprotein E1A activates the gene expression of all three subunits
of CBF/NF-Y, we sought to determine whether CBF/NF-Y plays any role in
E1A-mediated transactivation of the human cdc2 promoter.
Expression of E1A.12S results in transactivation of the human
cdc2 promoter/CAT reporter construct in RLE cells (43). To
test whether CBF/NF-Y is involved in E1A-mediated transactivation, RLE
cells were infected with adenovirus wild type E1A.12S and then
co-transfected with an expression plasmid encoding a dominant negative
mutant NF-YA subunit (NF-YA29) (51) in increasing dosage along with a
fixed amount of the cdc2 promoter/CAT reporter plasmid. Cell
extracts were then prepared and assayed for CAT activities (Fig.
7). The results shown in Fig. 7 indicated
that the transactivation of the cdc2 promoter by E1A was
significantly diminished by expression of the dominant negative NF-YA
mutant in a dose-dependent manner. These results support
the conclusion that NF-Y plays an important role in the E1A-mediated
transactivation of the human cdc2 promoter in cycling cells.
The evidence based on our results support the conclusion that
adenovirus E1A transactivates the human cdc2 gene expression
through a novel mechanism by inducing the expression and assembly of
individual components of the heteromeric complex involving the CBF/NF-Y
and the 110-kDa protein with the pentanucleotide CCAAT motifs and
its flanking sequences.
|
| |
DISCUSSION |
|---|
|
|
|---|
The transcriptional regulation of the human cdc2
promoter seems to be complex as it has multiple regulatory elements for
binding of several transcription factors (18, 55). Within the
359 region of the cdc2 promoter, the ATF, c-Myb, Sp1, and
E2F-binding sites as well as the two inverted CCAAT box motifs (at
positions
74 to
78 and
42 to
46) contribute to the basal
activity of the promoter (42). These CCAAT box motifs conform to the
consensus binding sites for the heterotrimeric and ubiquitous
transcription factor NF-Y (52) (for reviews, see Refs. 56 and 57).
Our previous studies indicated that the two CCAAT box binding motifs of the human cdc2 promoter were not only important for the basal activity of the promoter but also for the SV40-LT and adenovirus E1A-mediated transactivation of the promoter in cycling cells (42, 43). In those studies, a 110-kDa protein was shown to be induced by both viral oncoproteins. Using Southwestern blot analysis and EMSA, it was shown that this 110-kDa nuclear protein specifically bound the 180-bp DNA fragment spanning the two (both distal and proximal) CCAAT motifs of the human cdc2 promoter as well as the 29-bp DNA fragment containing only the distal CCAAT motif (42, 43). However, the mechanism of transactivation of the cdc2 gene by these viral oncoproteins and the role of this 110-kDa protein or the CCAAT motifs of the cdc2 promoter in transcriptional activation remained unclear.
In this study we provide evidence that this 110-kDa protein is a component of a heteromeric complex with ubiquitous transcription factor, CBF/NF-Y. Furthermore, our evidence, obtained using a dominant negative mutant expression clone of NF-YA subunit (NF-YA29 (51)), indicates that CBF/NF-Y plays an important role in the regulation of E1A-mediated transactivation of human cdc2 gene expression. This role of NF-Y in transactivation of a cell cycle-regulated cdc2 gene by an oncoprotein, E1A, is underscored by the findings that NF-Y-binding sites are also present in other cell cycle-regulated genes such as cyclin A, thymidine kinase, hsp70, and cdc25C (reviewed in Ref. 57). The presence of a single wild type CCAAT box motif of the cdc2 promoter was sufficient for transactivation by E1A 3-5-fold. However, when both CCAAT motifs were mutated, no specific DNA-protein complexes could be formed and transactivation of the cdc2 promoter by E1A was abolished (43). E1A has been shown to activate gene expression of cyclin A, thymidine kinase, and hsp70 (58-60), suggesting the possibility that NF-Y may also play a role in transactivation of these cell cycle regulatory genes. Supporting this notion is the observation that a complex of a 115-kDa protein and CBF/NF-Y was shown to interact with the CCAAT motif of the cyclin A promoter and this interaction is necessary for adhesion-dependent transcription of cyclin A gene (61). However, the binding specificity of the 115-kDa protein to the CCAAT motif of cyclin A promoter has not been analyzed.
Nuclear extracts from human 293 cells specifically bind the CCAAT box motifs of cdc2, cyclin A, cdc25C, and hsp70 promoters to form the specific DNA-protein complexes (43, 62). However, there are some differences in the patterns observed in EMSA; the distal CCAAT element of the cdc2 and cdc25C promoters and the CCAAT element of the hsp70 promoter formed three specific complexes (CI to CIII). However, the cyclin A promoter element and the proximal motif of the cdc2 promoter formed only complex I (Ref. 62 and this study). The complexes II and III formed with the distal motif of the cdc2 promoter were competed out by the cold oligonucleotides containing the distal cdc2 motif, suggesting that these are specific complexes. However, they did not include NF-Y as shown by supershift EMSA assays. Further work is necessary to identify the proteins interacting with the distal CCAAT element of not only the cdc2 promoter but also the cdc25C promoter and the CCAAT element in the hsp70 promoter.
Our previous observation that the basal activity of the mutant cdc2 promoter/reporter construct in which both CCAAT motifs were mutated was increased 1.75-fold compared with the wild type construct in the absence of adenovirus E1A (43), suggested a possibility that the wild type CCAAT motifs of the cdc2 gene may in fact mediate transcriptional repression in cycling cells rather than activation in the absence of E1A. The role of E1A in the activation of the cdc2 promoter may be to overcome this repression and couple upstream transcriptional activators to the basal transcription machinery. Consistent with this notion, cell cycle-dependent element (CDE)-mediated transcriptional repression, caused by binding of proteins to CDE, has been proposed as a mechanism to explain the periodic activation of cdc25C, cyclin A, and cdc2 during the cell cycle (63). Although promoters of all three genes contained the CDE element, only cdc2 and cdc25C promoters contained the two CCAAT elements (referred as Yc-Box1 and Yc-Box2 in Ref. 63). However, the cyclin A promoter contained only one CCAAT element which was similar to the consensus sequence present in the proximal cdc2 promoter.
In vivo footprinting studies suggested that a CDE mapping at
20 of the cdc2 promoter (64) and
15 of the
cdc25C promoter (65) with respect to the transcription start
site, together with cell cycle homology region (CHR), negatively
regulates the cdc2 gene expression (for review, see Ref.
66). CDE element is similar to the consensus E2F site except it lacks a
T-rich region upstream of the G/C core. The major protein complex
binding at
20 element of the cdc2 promoter is the
E2F-4/p130, formed between the member of E2F transcription factor
family and the E1A-associated protein of retinoblastoma protein family
(64). Furthermore, the E2F-4·p130 complex functioned as a repressor predominantly in quiescent cells and to some extent also in cycling cells (64). In the case of cdc25C promoter it was shown that for the transcriptional repression via the CDE-CHR regions, the upstream activating sequence which contains recognition sites for NF-Y
and Sp1, were also required (67). Therefore, the increased basal
activity of the cdc2 promoter by mutation of the two CCAAT motifs (43) suggests that NF-Y may also be under negative regulation of
CDE-CHR elements of the cdc2 promoter due to binding of
E2F-4/p130 in the absence of E1A. The role of E1A is then to relieve
this repression by multiple pathways. For example, E1A could disrupt the E2F-4·p130 complex by binding to the p130 (68), as the cells exit
G1 to enter S phase. As shown in the present study, E1A
also activates gene expression of all three subunits of CBF/NF-Y. The supporting evidence for the role of newly synthesized NF-Y playing an
important role in E1A-mediated transactivation of the cdc2 promoter comes from our results that the dominant negative mutant NF-YA
inhibits this transactivation. This inhibition could result from either
interference of the dominant negative mutant with the assembly of the
heterotrimeric NF-Y or interaction between NF-Y and the 110-kDa
CBAF/cdc2 or both.
The functional domains of E1A protein that are required for immortalization, cellular DNA synthesis, cdc2 gene expression, and p34Cdc2 kinase activity have been studied in detail by mutational analysis (22, 24, 69-71). E1A mutants defective in binding one or the other of pRB family or p300/CBP family of proteins were still capable of inducing DNA synthesis and p34Cdc2 kinase activity (22, 24, 72). However, E1A mutants which lost the ability to bind both families of proteins were defective in these functions. The requirement of the E1A domains for the induction of the 110-kDa CBAF also showed a similar pattern (43).
There are several proteins which are known to bind CCAAT motifs: CTF/NF-I (73), CBF/NF-Y (also known as CP1 (46, 54, 74)), CP2 (74), CBP (75), C/EBP (76), and a 114-kDa CBF which is involved in the activation of hsp70 promoter (77, 78) (referred here as CBF/HSP70). E1A.12S stimulated the transcription of the endogenous CBF/hsp70 gene (43). Moreover, the 114-kDa CBF/HSP70 also transactivated cdc2 promoter/reporter expression in transient transfection assays carried out in HeLa cells (43) but not in CV1 cells (42). These results suggest that the transactivation of the human cdc2 promoter by the ectopic expression of the CBF/HSP70 appears to depend on cell type. These observations are in accord with the previous report that the transactivation of the hsp70 promoter/reporter by CBF/HSP70 in transient transfection assays was also dependent on cell type; CBF/HSP70 was active in COS cells, which constitutively express SV40 large T antigen, but not in Chinese hamster overy cells (79). Co-transfection of E1A and the hsp70 promoter/CAT plasmid into Chinese hamster overy cells was necessary to transactivate the hsp70 promoter/CAT expression. We previously reported that heteromeric complex I, which includes the CBF/NF-Y and the 110-kDa protein as shown in this study, are overexpressed in HeLa cells and COS cells. The 110-kDa·NF-Y complex from COS cell or 293 cell nuclear extracts, bound to the distal CCAAT motif of the cdc2 promoter, was not supershifted by anti-CBF/HSP70 antibody (Ref. 42, data not shown) suggesting that complex I does not include the CBF/HSP70. These observations, taken together, suggest that prior induction of the 110-kDa protein by the viral oncoproteins may be required for activation of the hsp70 promoter by the 114-kDa CBF/HSP70 protein over the levels achieved with the 110 kDa·NF-Y complex alone.
Not only the cellular genes and/or host cell cycle are affected, the ability of E1A to activate NF-Y also might have a great impact on viral life cycle. The adenovirus major late promoter, one of the most intensively studied eukaryotic polymerase II promoters, has several regulatory binding sites for transcription factors, including an inverted CCAAT box that binds to NF-Y. In a recent study (80) on functional analysis of this CCAAT box in major late promoter revealed that mutation of this region greatly reduced the viral replication. Although the CCAAT sequence can be replaced by ATF- and OCT1-binding sites without losing its function, the CCAAT motif was still a preferred site (80) and it is highly conserved among mammalian adenoviruses.
NF-Y is known to function with other accessory DNA-binding proteins,
which serve as cooperative factors to achieve enhanced gene expression.
Some examples are, sterol regulatory element-binding protein in the
regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase gene (49),
Sp1 in the regulation of major histocompatibility complex class
II-associated invariant chain gene (81) as well as the human multiple
drug-resistance gene (82), RF-X, in the major histocompatibility
complex class II promoter regulation expression (83), C/EBP in
liver-specific albumin gene expression (48), C/EBP
in the regulation
mdr1b promoter (84) and Tax1 protein, encoded by human T-cell
lymphotropic virus type 1 (85), which is involved in transcriptional
activation of a number of cellular genes.
For the deregulation of cell cycle-regulated cdc2 gene
expression by the oncoprotein E1A, our study provides the first
evidence that both the 110-kDa CBAF and CBF/NF-Y are induced which form a heteromeric complex. There is increasing evidence that aberrations in
expression of cell cycle regulatory proteins such as cyclins, CDKs, and
CDK inhibitors are closely linked to development and progression of
carcinogenesis. Deregulation of cell cycle control is a hallmark of
cancer cells (86-90). We recently reported that the 110-kDa CBAF is
overexpressed in a variety of human tumor cell lines and rodent cell
lines transformed by different oncogenes or spontaneously (62).
Therefore, the results presented in this study taken together with
previous studies suggest that aberrant expression of the components of
the heteromeric protein complex, the 110-kDa CBAF/cdc2 and NF-Y, may
play an important role in carcinogenesis.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. J. Campisi for the pCMV-cdc2 plasmid, E. Moran for the adenovirus E1A.12S, S. Thorgeirsson for the RLE cells, S. Maity for the plasmids encoding NF-Y A, B, and C subunits, and R. Mantovani for the dominant negative mutant NF-YA29 plasmid.
| |
FOOTNOTES |
|---|
* This work was supported by a National Science Foundation Grant MCB-9507034 (to R. P.) and funds from the Department of Pathology and Cell Biology, University of Occupational and Environmental Health, Kitakyushu, Japan (to Y. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Contributed equally to the results of this study.
¶ Present address: Dept. of Pathology and Cell Biology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807, Japan.
** To whom correspondence and reprint requests should be addressed: Dept. of Biochemistry and Molecular Biology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7421. Tel.: 913-588-7018; Fax: 913-588-7440; E-mail: rpadmana@kumc.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: CDK, cyclin-dependent kinase; c/EBP, CCAAT/enchancer-binding protein; RLE, rat liver epithelial cell; EMSA, electrophoretic mobility shift assay; bp, base pair(s); PAGE, polyacrylamide gel electrophoresis; CAT, chloramphenicol acetyltransferase; CDE, cell cycle-dependent element; CHR, cell cycle homology region.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Nurse, P., and Bissett, Y. (1981) Nature 292, 558-560[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Beach, D., Durkacz, B., and Nurse, P. (1982) Nature 300, 706-709[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Reed, S. I.,
Hadwiger, J. A.,
and Lorincz, A. T.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
4055-4059 |
| 4. | Simanis, V., and Nurse, P. (1986) Cell 45, 261-268[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Draetta, G., Brizuela, L., Potashkin, J., and Beach, D. (1987) Cell 50, 319-325[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Lee, M. G., and Nurse, P. (1987) Nature 327, 31-35[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Riabowol, K., Draetta, G., Brizuela, L., Vandre, D., and Beach, D. (1989) Cell 57, 393-401[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Fang, F., and Newport, J. W. (1991) Cell 66, 731-742[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Murray, A. W. (1992) Nature 359, 599-604[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Draetta, G. (1990) Trends Biochem. Sci. 15, 378-383[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Murray, A. W. (1995) Curr. Opin. Genet. Dev. 5, 5-11[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Pines, J. (1995) Semin. Cancer Biol. 6, 63-72[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Grana, X., and Reddy, E. P. (1995) Oncogene 11, 211-219[Medline] [Order article via Infotrieve] |
| 14. | Tsai, L.-H., Harlow, E., and Meyerson, M. (1991) Nature 353, 174-177[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Pagano, M.,
Pepperkok, R.,
Lukas, J.,
Baldin, V.,
Ansorge, W.,
Bartek, J.,
and Draetta, G.
(1993)
J. Cell Biol.
121,
101-111 |
| 16. | Morgan, D. O. (1995) Nature 374, 131-134[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
D'Urso, G.,
Marraccino, R. L.,
Marshak, D. R.,
and Roberts, J. M.
(1990)
Science
250,
786-791 |
| 18. | Dalton, S. (1992) EMBO J. 11, 1797-1804[Medline] [Order article via Infotrieve] |
| 19. | Draetta, G., and Beach, D. (1988) Cell 54, 17-26[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Krek, W., and Nigg, E. A. (1989) EMBO J. 8, 3071-3078[Medline] [Order article via Infotrieve] |
| 21. | Lee, M. G., Norbury, C. J., Spurr, N. K., and Nurse, P. (1988) Nature 333, 676-679[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Wang, H. G.,
Draetta, G.,
and Moran, E.
(1991)
Mol. Cell. Biol.
11,
4253-4265 |
| 23. | Draetta, G., Beach, D., and Moran, E. (1988) Oncogene 2, 553-557[Medline] [Order article via Infotrieve] |
| 24. |
Howe, J. A.,
Mymryk, J. S.,
Egan, C.,
Branton, P. E.,
and Bayley, S. T.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
5883-5887 |
| 25. | Buchkovich, K., Duffy, L. A., and Harlow, E. (1989) Cell 58, 1097-1105[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J. Y., Huang, C. M., Lee, W. H., Marsilio, E., Paucha, E., and Livingston, D. M. (1988) Cell 54, 275-283[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Lee, E. Y.,
To, H.,
Shew, J. Y.,
Bookstein, R.,
Scully, P.,
and Lee, W. H.
(1988)
Science
241,
218-221 |
| 28. |
Horowitz, J. M.,
Park, S. H.,
Bogenmann, E.,
Cheng, J. C.,
Yandell, D. W.,
Kaye, F. J.,
Minna, J. D.,
Dryja, T. P.,
and Weinberg, R. A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2775-2779 |
| 29. | Cress, W. D., and Nevins, J. R. (1996) Curr. Top. Microbiol. Immunol. 208, 63-78[Medline] [Order article via Infotrieve] |
| 30. | Nevins, J. R. (1994) Curr. Opin. Genet. Dev. 4, 130-134[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Beck, G. R. J., Zerler, B., and Moran, E. (1998) in Human Tumor Viruses (McCance, D. J., ed) , American Society for Microbiology Press, Washington, D. C., in press |
| 32. | Whyte, P., Buchkovich, K. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., and Harlow, E. (1988) Nature 334, 124-129[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Dyson, N.,
Howley, P. M.,
Munger, K.,
and Harlow, E.
(1989)
Science
243,
934-937 |
| 34. | Bandara, L. R., and La Thangue, N. B. (1991) Nature 351, 494-497[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Chellappan, S.,
Kraus, V. B.,
Kroger, B.,
Munger, K.,
Howley, P. M.,
Phelps, W. C.,
and Nevins, J. R.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
4549-4553 |
| 36. | Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., and Kelly, K. (1997) Cell 89, 1175-1184[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Gu, W., Shi, X.-L., and Roeder, R. G. (1997) Nature 387, 823-827[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., and Livingston, D. M. (1997) Nature 387, 823-827 |
| 39. |
Scolnick, D. M.,
Chehab, N. H.,
Stavridi, E. S.,
Lien, M. C.,
Caruso, L.,
Moran, E.,
Berger, S. L.,
and Halazonetis, T. D.
(1997)
Cancer Res.
57,
3693-3696 |
| 40. | Somasundaram, K., and El Deiry, W. S. (1997) Oncogene 14, 1047-1057[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Mal, A., Poon, R. Y., Howe, P. H., Toyoshima, H., Hunter, T., and Harter, M. L. (1996) Nature 380, 262-265[CrossRef][Medline] [Order article via Infotrieve] |
| 42. |
Chen, H.,
Campisi, J.,
and Padmanabhan, R.
(1996)
J. Biol. Chem.
271,
13959-13967 |
| 43. | Tanimoto, A., Chen, H., Kao, C., Moran, E., Sasaguri, Y., and Padmanbhan, R. (1998) Oncogene 17, 3103-3114[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Bucher, P. (1990) J. Mol. Biol. 212, 563-578[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | van Huisjduijnen, R. H., Li, X. Y., Black, D., Matthes, H., Benoist, C., and Mathis, D. (1990) EMBO J. 9, 3119-3127[Medline] [Order article via Infotrieve] |
| 46. | Maity, S. N., Golumb |